# Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

> **NCT05600686** · PHASE2 · RECRUITING · sponsor: **Joseph Tuscano** · enrollment: 24 (estimated)

## Conditions studied

- Double-Expressor Lymphoma
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **BIOLOGICAL:** Loncastuximab Tesirine
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT05600686
- **Lead sponsor:** Joseph Tuscano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-24
- **Primary completion:** 2026-02-01
- **Final completion:** 2028-02-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-11-25

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05600686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05600686, "Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05600686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*